- Home
- TPIC vs ACRV Comparison
TPIC vs ACRV Comparison
Compare TPIC & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPIC
- ACRV
- Stock Information
- Founded
- TPIC 1968
- ACRV 2018
- Country
- TPIC United States
- ACRV United States
- Employees
- TPIC N/A
- ACRV N/A
- Industry
- TPIC Industrial Machinery/Components
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- TPIC Industrials
- ACRV Health Care
- Exchange
- TPIC Nasdaq
- ACRV Nasdaq
- Market Cap
- TPIC 207.8M
- ACRV 247.8M
- IPO Year
- TPIC 2016
- ACRV 2022
- Fundamental
- Price
- TPIC $2.17
- ACRV $6.96
- Analyst Decision
- TPIC Hold
- ACRV Strong Buy
- Analyst Count
- TPIC 5
- ACRV 5
- Target Price
- TPIC $4.49
- ACRV $22.40
- AVG Volume (30 Days)
- TPIC 857.6K
- ACRV 47.9K
- Earning Date
- TPIC 11-07-2024
- ACRV 11-13-2024
- Dividend Yield
- TPIC N/A
- ACRV N/A
- EPS Growth
- TPIC N/A
- ACRV N/A
- EPS
- TPIC N/A
- ACRV N/A
- Revenue
- TPIC $1,301,740,000.00
- ACRV N/A
- Revenue This Year
- TPIC N/A
- ACRV N/A
- Revenue Next Year
- TPIC $23.03
- ACRV N/A
- P/E Ratio
- TPIC N/A
- ACRV N/A
- Revenue Growth
- TPIC N/A
- ACRV N/A
- 52 Week Low
- TPIC $1.90
- ACRV $3.19
- 52 Week High
- TPIC $5.75
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- TPIC 28.13
- ACRV 34.20
- Support Level
- TPIC $2.11
- ACRV $7.69
- Resistance Level
- TPIC $2.53
- ACRV $8.54
- Average True Range (ATR)
- TPIC 0.31
- ACRV 0.44
- MACD
- TPIC -0.10
- ACRV -0.10
- Stochastic Oscillator
- TPIC 3.63
- ACRV 3.78
About TPIC TPI Composites Inc.
TPI Composites Inc is engaged in manufacturing composite wind blades. The company operates in wind energy and transportation industries where it manufactures structures for a bus, rail, theme parks, and trucks. Geographically the segments are divided into the U.S, Asia, Mexico, EMEA and India where the Mexico segment derives a majority of revenue.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.